Skip to content

activating the Immune response In ovarian cancer study

activating the Immune response In ovarian cancer study - ACTION study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON56684
Enrollment
90
Registered
2024-04-10
Start date
2024-09-03
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian carcinoma

Interventions

None listed

Sponsors

Catharina-ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Subjects should be at least 18 years old and mentally competent -Newly diagnosed patients with ovarian carcinoma (OC) who go for primary debulking surgery or patients with OC are scheduled for interval debulking - Controls: women who undergo surgery for benign gynaecological conditions under general anaesthesia

Exclusion criteria

Exclusion criteria: -Mentally incompetent -Pregnant or breastfeeding -Known inflammatory or infectious diseases or an immunosuppressive status -Using medication interfering with the immune system -Severe comorbidities: other active malignancy (except for basal cell carcinoma and other in situ carcinomas) -Serious psychiatric pathology -A self-reported alcohol consumption of >21 units per week -Bleedings disorder -History of splenectomy -Not mastering the Dutch language

Design outcomes

Primary

MeasureTime frame
Characterizing the immune status of ovarian carcinoma patients compared to cancer-free controls, with a focus on hematopoietic organs and the immune cells originating from them. This will be accomplished by assessing the transcriptional, epigenetic, and functional programming of circulating monocytes and myeloid precursor cells in OC.

Secondary

MeasureTime frame
none

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)